

VOLUME 4

MAY 2021

Number
of
Patients
Enrolled **163**

Number
of
Sites
Initiated **42**

HALO


Heparin Anticoagulation to improve Outcomes in septic shock: The HALO International Phase II RCT

HALO At-A-Glance!

A global trial evaluating the efficacy and safety of the use of unfractionated heparin (UFH) to improve outcomes in patients with vasodilatory shock.

We would like to start by thanking everyone for their continued dedication to HALO during the COVID-19 pandemic. Every site faced its set of challenges that came with the pandemic. Before the start of the pandemic HALO enrollment was steadily increasing with a record 17 patients enrolled in February 2020. Since the start of the pandemic, we have seen an average of 6 patients enrolled monthly.

Since January of this year, 27 participants have been enrolled into HALO, which brings the total to 163. The Data Safety Monitoring Board will be meeting for an interim analysis when we reach 170 participants.



As HALO looks at concluding in the next year, we hope to enroll as many patients as possible to strengthen our analysis of the efficacy of heparin in patients with sepsis.



CONGRATULATIONS!

Congratulations everyone for your hard work and thank you for your continued efforts!



2020 Recap

1. A total of **97 patients** were randomized
2. In January, we activated our **first site in the United States** (Froedtert Hospital in Milwaukee, WI)
3. In February, our **first patient was enrolled in Greece** (Korgialeneion Benakeion Hospital)
4. In July, Hospital Nereu Ramos (Brazil) enrolled **HALO's 100th patient**



24 sites were activated: 1 in the United States and 23 in Brazil

A total of 11 sites enrolled their first patient:

- Hospital de Amor (Brazil) on January 3rd
- St Michael's Hospital (Canada) on January 7th
- Hospital São José (Brazil) on January 10th
- Hospital AC Camargo (Brazil) on February 1st
- Calgary Foothills (Canada) on February 9th
- Korgialeneion Benakeion Hospital (Greece) on February 25th
- Hospital Maternidade São José (Brazil) on May 3rd
- Universidade Federal de Sao Paulo (Brazil) on July 8th
- IUPC Quebec (Canada) on July 13th
- Unimed Cariri Hospital (Brazil) on Aug 28th
- Hospital de Brasília (Brazil) on October 28th

If you are interested in reading more about how HALO helped launch COVID-19 clinical trials looking at heparin, you can read the (pre-published) results of the severe state paper here:

<https://www.medrxiv.org/content/10.1101/2021.05.13.21256846v1>



International Updates



Pakistan:

Last month we had a site initiation visit with The Indus Hospital and we expect them to start enrolling shortly! This month we had an initiation visit with the Dow University team, which includes two sites: The SMBB Institute of Trauma and Dr. Ruth K.M. PFAU Hospital both in the city of Karachi.



Philippines:

We have finalized a clinical trial agreement with the Medical City Hospital and hope to have them activated shortly. We are also starting the process of initiating two other sites: Philippines General Hospital and The Asian Hospital.



Brazil:

HCor has done an incredible job identifying and activating nearly thirty sites! Brazil is five patients away from enrolling a total of 100 patient.




India:

Indoriv is working towards getting AMRI re-initiated and are looking at a second site. We will be having a site initiation visit with them at the end of the month.



Canada:

Winnipeg has added a third site, the Grace Hospital. We also had the pleasure of meeting with the expanding St. Catharines HALO team for a training session in March.



Principal Investigators

Dr. Ryan Zarychanski
rzarychanski@cancercare.mb.ca | 1-204-899-4288

Dr. Anand Kumar
akumar61@yahoo.com | 1-204-291-0372

Project Leads

Nicole Marten, RN
nmarten@sbgh.mb.ca
Chantale Pineau
cpineau@sbgh.mb.ca
1-204-235-3223

CONTACT
US

HALO Coordinating Centre | Health Sciences Centre Winnipeg | Isabel M. Stewart Building Room NA 459
700 McDermot Avenue | Winnipeg, MB R3E 0T2 | Tel: (204) 787.1224 | HALO@exchange.hsc.mb.ca